AOD-9604 + MOTS-c Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: combined lipid and mitochondrial metabolism

Metabolic Blend blend Blend verified

Also known as: AOD/MOTS

Quick Facts

Reference Sizes
No standardized fixed-blend SKU found - components are commonly sold separately
Components
AOD-9604 + MOTS-c
Calculator
Preset available
Storage
Use source-label storage wording. Track lot, storage location, and open/reconstitution date.
Solubility
Component-specific; no validated mixed-formulation solvent or compatibility study exists

Blend Components

This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.

Component
AOD-9604
Calculator Profile
Component
MOTS-c
Calculator Profile
Open All in Blend Calculator

Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.

Catalog Description

AOD-9604 + MOTS-c combines AOD-9604 + MOTS-c into a single research protocol. Each component is independently studied; this entry summarizes the individual evidence base for the combination, since no unified safety/efficacy dataset covers the mixed formulation unless noted below. AOD-9604: Modified HGH fragment 176-191 (beta-3 adrenergic agonist for lipolysis); 23-week RCT showed modest weight loss over placebo, but the largest Phase IIb trial missed statistical significance and development was discontinued (2007). MOTS-c: Mitochondrial-derived peptide (12S rRNA-encoded) studied for AMPK-linked metabolic regulation and exercise-mimetic effects; preclinical biology well-characterized, zero completed human interventional trials as of 2026. This is a community-stacking combination assembled from two independently studied compounds rather than a pharmaceutical sponsor's dedicated fixed-dose combination program - no dedicated human combination trial exists for this exact pairing as of this writing.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life
Varies by component - see individual compound half-life data; no combined-formulation pharmacokinetic study exists
Onset
Varies by component - see individual compound onset data
Administration Routes (Research)
SCOral (some formulations studied)SC (research use)

Reported Research Effects

Reported Research Side Effects

Data source: Derived from independently verified single-compound research profiles (see component sources); no dedicated combination trial for this exact pairing

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

Research Notes

Current market checks found AOD-9604 and MOTS-c sold separately in multiple vial sizes but did not establish a standardized 20 mg fixed blend. Keep this record only if the site intentionally supports conceptual community combinations.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans — Journal of Endocrinology and Metabolism
https://www.jofem.org/index.php/jofem/article/view/157/194
FDA briefing document discussing MOTS-c evidence and regulatory review — U.S. Food and Drug Administration
https://www.fda.gov/media/193347/download

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top